India’s crime agency searched premises linked to a cough-syrup manufacturer associated with child fatalities abroad, escalating regulatory scrutiny on pharmaceutical exports. Authorities sought documents on formulation practices, batch records and export clearances. The probes come as New Delhi tightens quality oversight to protect reputation and market access. Pharma investors are assessing potential compliance costs, production disruptions and liability implications. Export-oriented firms may face closer audits, with any adverse findings possibly affecting approvals, pricing negotiations and overseas procurement tenders.